Home › Trial NCT00065533
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
- Trial IDNCT00065533
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorEli Lilly and Company
- Enrollment92
- Start date2003-05
- ConditionsBreast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.